An Overview of Pharmacological and Non-Pharmacological Treatment as a Useful Tool for the Protection from Cardiotoxicity of Antineoplastic Drugs

1. Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics, Accessed: May, 2018.Search in Google Scholar

2. Ilic M, Ilic I. Cancer mortality in Serbia, 1991-2015: an age-period-cohort and joinpoint regression analysis. Cancer Commun (Lond). 2018 Apr 10;38(1):10.10.1186/s40880-018-0282-3Search in Google Scholar

3. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.10.1093/jnci/djp440Search in Google Scholar

4. Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L’Allemain G, Bay JO. [Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer]. Bull Cancer. 2018;105(1):6-14.10.1016/j.bulcan.2017.11.006Search in Google Scholar

5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263-302.10.2165/00002018-200022040-00002Search in Google Scholar

6. Albini A, Pannesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.10.1093/jnci/djp440Search in Google Scholar

7. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21:173–179.10.1093/annonc/mdq295Search in Google Scholar

8. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213–220.10.1016/j.jacc.2009.03.095Search in Google Scholar

9. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracicline therapy. JAMA. 1991;266:1672–1677.10.1001/jama.1991.03470120074036Search in Google Scholar

10. Stevens PL, Lenihan DJ. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers. Curr Cardiol Rep. 2015 Jul;17(7):603.10.1007/s11886-015-0603-ySearch in Google Scholar

11. ltena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391–399.10.1016/S1470-2045(09)70042-7Search in Google Scholar

12. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basicunder-lying mechanisms. Pharmacol Ther. 2018; S0163-7258(18)30072-X.10.1016/j.pharmthera.2018.04.009Search in Google Scholar

13. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Ver-rill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.10.1186/1471-2407-10-337Search in Google Scholar

14. SNPC. European Medicine Agency. Available in: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000682/human_med_001047.jsp&mid=WC0b01ac058001d124Search in Google Scholar

15. Cvetkovic RS, Scott LJ. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemo-therapy. Drugs. 2005;68:1005–1024.Search in Google Scholar

16. Csapo M, Lazar L. Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention. Clujul Medical. 2014;87(3):135-142.Search in Google Scholar

17. SNPC. Food and Drug Agency. Available in: https://www.fda.gov/Drugs; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020212Search in Google Scholar

18. Boucek RJ, Jr, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3:319–29.10.1385/CT:3:4:319Search in Google Scholar

19. Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469–73.10.1002/jat.78211746193Search in Google Scholar

20. Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142:396–403.10.1016/j.jtcvs.2010.07.097317351221094500Search in Google Scholar

21. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60:373–81.10.1016/j.phrs.2009.05.00719467331Search in Google Scholar

22. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 2013; 61: 2355–2362.10.1016/j.jacc.2013.02.07223583763Search in Google Scholar

23. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009; 69: 695–699.10.1158/0008-5472.CAN-08-307619147586Search in Google Scholar

24. Gnad R, Kaina B, Fritz G. Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. Exp Cell Res 2001; 264: 244–249.10.1006/excr.2001.516511262181Search in Google Scholar

25. Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2011; 2: e190.10.1038/cddis.2011.65318141521833028Search in Google Scholar

26. Ramanjaneyulu SV, Trivedi PP, Kushwaha S, Vikram A, Jena GB. Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. J Physiol Biochem 2013; 69: 513–525.10.1007/s13105-013-0240-0Search in Google Scholar

27. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.10.1007/s11897-017-0353-9Search in Google Scholar

28. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.10.1016/j.jacc.2006.07.052Search in Google Scholar

29. Pimprapa V, Edward Y. Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities. Journal of the American College of Cardiology. 2014; 64(9): 938-945.10.1016/j.jacc.2014.06.1167Search in Google Scholar

30. Mônica Samuel Avila, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Vagner Oliveira Carvalho Rigaud, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity Journal of the American College of Cardiology. 2018; 71 (20) 2281-2290.10.1016/j.jacc.2018.02.049Search in Google Scholar

31. Purva Sharma, Stephanie Hakimian, Juan Camacho and Robert Chait. Prevention of chemo-induced cardiotoxicity with beta-blockers. Journal of the American College of Cardiology, 2018;71(11); DOI: 10.1016/S0735-1097(18)32344-1.10.1016/S0735-1097(18)32344-1Search in Google Scholar

32. Escudier B, Alexandre JB, Leclercq B, Morin P, Guyot JM, Nitenberg G. Cardiotoxicitt du 5-fluorouracil. Caract Cristiques, mkanisme, conduite pratique. Presse Med 1986; 15:6-11.Search in Google Scholar

33. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.10.1016/j.jacc.2009.02.05019520246Search in Google Scholar

34. Puel C, Mathey J, Agalias A, Kati-Coulibaly S, Mardon J, et al. Dose–response study of effect of oleuropein, an olive oil polyphenol, in an ovariectomy/inflammation experimental model of bone loss in the rat. Clin. Nutr 2006; 25, 859–868.10.1016/j.clnu.2006.03.00916740345Search in Google Scholar

35. Gülkaç MD, Akpinar G, Ustün H, Ozön Kanli A. Effects of vitamin A on doxorubicin-induced chromosomal aberrations in bone marrow cells of rats. Mutagenesis 2004; 19, 231–236.10.1093/mutage/geh02115123789Search in Google Scholar

36. Santos RV, Batista Jr, ML, Caperuto EC, Costa Rosa LF. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats. Clin. Exp. Pharmacol. Physiol. 2007; 34:1294–1299.Search in Google Scholar

37. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther 2005; 4:110–130.10.1177/153473540527619115911925Search in Google Scholar

38. Huertas JR, Battino M, Lenaz G, Mataix FJ. Changes in mitochondrial and microsomal rat liver coenzyme Q9 and Q10 content induced by dietary fat and endogenous lipid peroxidation. FEBS Lett. 1991; 287:89–92.10.1016/0014-5793(91)80022-USearch in Google Scholar

39. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 2009;486:95–102.Search in Google Scholar

40. Goulas V, Exarchou V, Troganis AN, Psomiadou E, Fotsis T, Briasoulis E, Gerothanassis IP. Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells. Mol. Nutr. Food Res. 2009; 53, 600–608.Search in Google Scholar

41. Quiles JL, Huertas JR, Battino M, Mataix J, Ramírez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002; 180:79–95.10.1016/S0300-483X(02)00383-9Search in Google Scholar

42. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK. Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol. 2003; 3:16–24.10.1186/1471-2210-3-1632440114687418Search in Google Scholar

43. Lim HA, Kim JH, Kim JH, Sung MK, Kim MK, Park, JH, Kim JS. Genistein induces glucose-regulated protein 78 in mammary tumor cells. J. Med. Food 2006; 9:28–32.Search in Google Scholar

44. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr. Rev. 2008; 66:445–454.Search in Google Scholar

45. Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, Aydin A, et al. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol. Trace Elem. Res. 2009; 14:25-31.Search in Google Scholar

46. Bulucu F, Oktenli C, Kenar L, Ocal R, Koc B, Inal V, Yamanel L, Yaman H, Sanisoglu YS, Aydin A. Efficacy of deferoxamine, N-acetylcysteine and selenium treatments in rats with adriamycin-induced nephrotic syndrome. J. Nephrol. 2008; 21: 576–583.Search in Google Scholar

47. Jemai H, El Feki A, Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats. J. Agric. Food Chem. 2009; 57:8798–8804.10.1021/jf901280r19725535Search in Google Scholar

48. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008; 259:111–118.10.1016/j.canlet.2007.10.00318006147Search in Google Scholar

49. Monstrey SJ, Mullick P, Narayanan K, et al. Hyperbaric oxygen therapy and free radical production: An experimental study in doxorubicin (Adriamycin) extravasation injuries. Ann Plast Surg 1997; 38:163-168.10.1097/00000637-199702000-000119043586Search in Google Scholar

50. Akta S, Toklu AS, Olgac V. Hyperbaric oxygen therapy in Adriamycin extravasation: An experimental animal study. Ann Plast Surg 2000; 45:167-171.10.1097/00000637-200045020-0001210949345Search in Google Scholar

51. Karagoz B, Suleymanoglu S, Uzun G, Bilgi O, Aydinoz S, Haholu A, Turken O,Onem Y, Kandemir EG. Hyper-baric oxygen therapy does not potentiatedoxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol. 2008;102(3):287-92.10.1111/j.1742-7843.2007.00196.x18248515Search in Google Scholar

52. Goolsby, Tiffany V. et al. Extravasation of Chemotherapeutic Agents: Prevention and TreatmentSeminars in Oncology. 2006; 33(1); 139-143.10.1053/j.seminoncol.2005.11.00716473651Search in Google Scholar

53. Newton RU, Galvão DA. Exercise in prevention and management of cancer. Curr Treat Options Oncol. 2008;9(2-3):135-46.10.1007/s11864-008-0065-118704691Search in Google Scholar

54. Rajarajeswaran P, Vishnupriya R. Exercise in cancer. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology. 2009;30(2):61-70.10.4103/0971-5851.60050288588220596305Search in Google Scholar

55. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.10.1007/s11897-017-0353-928779279Search in Google Scholar

56. Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. Jpn J Clin Oncol. 2016;34:2743–9.10.1200/JCO.2015.65.6603501974627217451Search in Google Scholar

57. Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res. 2009; 15:4963–7.10.1158/1078-0432.CCR-09-062819622583Search in Google Scholar

58. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology - Heart and Circula-tory Physiology. 2015; 309(9):H1453-H1467.10.1152/ajpheart.00554.2015466697426386112Search in Google Scholar

59. Fandeev OA, Vasechkin SS, Alekhin MN, Odintsov SV, Kallistov VE, Sidorenko BA. Clinical value of antracycline toxicity: modern approaches to diagnosis,prevention, and treatment. Kardiologiia. 2011; 51(7):40-6.Search in Google Scholar